Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00141765 · ClinicalTrials.gov registry record · Phase 2

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target

NCT00141765: Completed Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.

NCT00141765 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00141765, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.

Primary Outcome

The primary outcome measure for this study was to improve the long-term disease-free survival of patients with rare cancers at high risk for lethal relapse.

Interventions

  • PROCEDURE Myeloablative Chemotherapy
  • PROCEDURE Stem Cell Rescue

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 1997-01
Est. Completion 2010-02
Phase Phase 2

What the finished NCT00141765 record still lists

NCT00141765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).

The record links to 0 conditions, and to 2 interventions - of which Myeloablative Chemotherapy is the first listed.

NCT00141765 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00141765 about?

NCT00141765 is a clinical study titled "Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers". The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.

What is the current status of trial NCT00141765?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1997-01. Estimated completion is 2010-02.

What interventions are being tested in trial NCT00141765?

The interventions under investigation include: Myeloablative Chemotherapy (PROCEDURE), Stem Cell Rescue (PROCEDURE).

Who is sponsoring clinical trial NCT00141765?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00141765's enrollment target sits among peer trials

25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00141765, the US trial registry maintained by the National Library of Medicine. NCT00141765 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.